{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T15:48:58Z","timestamp":1783784938439,"version":"3.55.0"},"reference-count":64,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Metreleptin is a form of leptin replacement therapy used with diet and lifestyle modifications to treat the metabolic complications of leptin deficiency in lipodystrophy, a rare disease characterized by adipose tissue deficiency. Previously, identification of T-cell lymphomas in three metreleptin-treated patients with acquired generalized lipodystrophy (AGL) suggested a possible relationship between metreleptin and lymphoma development. To further investigate this, we performed a real-world pharmacovigilance assessment and literature review to identify lymphomas in patients with lipodystrophy and congenital leptin deficiency (CLD) who were either metreleptin-na\u00efve, or who had previously received\/were receiving metreleptin at the time of lymphoma diagnosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Cases were identified from PubMed, Embase and the Cochrane Library (from database inception through to November 22, 2024), and through review of 11 years post-marketing data from the global safety database (GSD) of the marketing authorization holder for metreleptin.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The final analysis set comprised 17 lymphomas in 16 patients reported in 11 published articles and one GSD case report. Twelve lymphomas were recorded in 12 metreleptin-na\u00efve patients \u2014 these comprised six T-cell lymphomas (one each in six patients with AGL), three B-cell lymphomas (in two patients with familial partial lipodystrophy and one patient with AGL), and three Hodgkin lymphomas (separately reported in one patient each with generalized lipodystrophy, juvenile-onset dermatomyositis-associated lipodystrophy, and CLD). Five lymphomas were identified in four metreleptin-treated patients, three of whom (all with AGL and T-cell lymphomas) were reported in previously published studies. The remaining metreleptin-treated patient (from the GSD) had generalized lipodystrophy-associated atypical progeroid syndrome and developed a B-cell lymphoma and brain lymphoma following solid organ transplantation and immunosuppressant therapy. All nine T-cell lymphomas occurred in patients with AGL, and additional autoimmune and\/or inflammatory disorders were commonly reported in these patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>While a contributory role for metreleptin in lymphoma development in patients with lipodystrophy cannot be excluded, our analysis suggests that lymphoma development may be associated with underlying pathophysiology that also leads to lipodystrophy rather than the pharmacological actions of metreleptin. Our findings support the view that, in some instances, immunoproliferative disorders of T-cells may contribute to syndromes involving autoimmune processes, including AGL.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2025.1582715","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T04:10:43Z","timestamp":1747800643000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["A real-world pharmacovigilance assessment and literature review of lymphoma development in lipodystrophy"],"prefix":"10.3389","volume":"16","author":[{"given":"Rebecca J.","family":"Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Araujo-Vilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly J.","family":"Walkovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandru","family":"Barbarosie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Magee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baris","family":"Akinci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif A.","family":"Oral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-2466","article-title":"The diagnosis and management of lipodystrophy syndromes: A multi-society practice guideline","volume":"101","author":"Brown","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra025261","article-title":"Acquired and inherited lipodystrophies","volume":"350","author":"Garg","year":"2004","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-1159","article-title":"Clinical review: lipodystrophies: genetic and acquired body fat disorders","volume":"96","author":"Garg","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B4","volume-title":"Lipodystrophy syndromes: presentation and treatment","author":"Akinci","year":"2000"},{"key":"B5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2337\/db21-1086","article-title":"Characterization and clinical association of autoantibodies against perilipin 1 in patients with acquired generalized lipodystrophy","volume":"72","author":"Corvillo","year":"2023","journal-title":"Diabetes"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2017.01.012","article-title":"Genetics of lipodystrophy","volume":"46","author":"Lightbourne","year":"2017","journal-title":"Endocrinol Metab Clin North Am"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-200303000-00007","article-title":"Clinical features and metabolic derangements in acquired generalized lipodystrophy: case reports and review of the literature","volume":"82","author":"Misra","year":"2003","journal-title":"Med (Baltimore)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/01.md.0000111061.69212.59","article-title":"Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature","volume":"83","author":"Misra","year":"2004","journal-title":"Med (Baltimore)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-019-0095-y","article-title":"Leptin and the endocrine control of energy balance","volume":"1","author":"Friedman","year":"2019","journal-title":"Nat Metab"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1210\/jcem.87.5.8624","article-title":"Serum adiponectin and leptin levels in patients with lipodystrophies","volume":"87","author":"Haque","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-02730","article-title":"Comorbidities and survival in patients with lipodystrophy: an international chart review study","volume":"104","author":"Akinci","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1250203","article-title":"Natural history and comorbidities of generalized and partial lipodystrophy syndromes in Spain","volume":"14","author":"Fernandez-Pombo","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15882","article-title":"A cohort analysis of familial partial lipodystrophy from two mediterranean countries","volume":"26","author":"Fernandez-Pombo","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909163411204","article-title":"Effects of recombinant leptin therapy in a child with congenital leptin deficiency","volume":"341","author":"Farooqi","year":"1999","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/43185","article-title":"Congenital leptin deficiency is associated with severe early-onset obesity in humans","volume":"387","author":"Montague","year":"1997","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/ng0398-213","article-title":"A leptin missense mutation associated with hypogonadism and morbid obesity","volume":"18","author":"Strobel","year":"1998","journal-title":". Nat Genet"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae149","article-title":"Classification of congenital leptin deficiency","volume":"109","author":"von Schnurbein","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012437","article-title":"Leptin-replacement therapy for lipodystrophy","volume":"346","author":"Oral","year":"2002","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-018-1589-1","article-title":"Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy","volume":"60","author":"Brown","year":"2018","journal-title":"Endocrine"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-019-01862-8","article-title":"Long-term effectiveness and safety of metreleptin in the treatment of patients with partial lipodystrophy","volume":"64","author":"Oral","year":"2019","journal-title":"Endocrine"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0074-7","article-title":"Metreleptin: first global approval","volume":"73","author":"Chou","year":"2013","journal-title":"Drugs"},{"key":"B22","unstructured":"Press release: shionogi receives marketing and manufacturing approval of a drug for lipodystrophy\n          \n          2013"},{"key":"B23","unstructured":"Myalept\u2122 Prescribing information\n          \n          2022"},{"key":"B24","unstructured":"Myalepta EU summary of product characteristics\n          \n          2023"},{"key":"B25","unstructured":"Myalepta UK summary of product characteristics\n          \n          2023"},{"key":"B26","unstructured":"Myalept (Metreleptina): novo registro\n          \n          2024"},{"key":"B27","unstructured":"Product monograph: myalepta\u2122 Metreleptin for injection\n          \n          2024"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1172\/JCI15693","article-title":"Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine\/metabolic dysfunction of human congenital leptin deficiency","volume":"110","author":"Farooqi","year":"2002","journal-title":"J Clin Invest"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204041","article-title":"Rare antagonistic leptin variants and severe, early-onset obesity","volume":"388","author":"Funcke","year":"2023","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3109\/10428194.2015.1040015","article-title":"Lymphoma in acquired generalized lipodystrophy","volume":"57","author":"Brown","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"B31","unstructured":"Medical dictionary for regulatory activities\n          \n          2024"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-014-0450-4","article-title":"Recombinant human leptin treatment in genetic lipodystrophic syndromes: the long-term spanish experience","volume":"49","author":"Araujo-Vilar","year":"2015","journal-title":"Endocrine"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-02078","article-title":"A novel generalized lipodystrophy-associated progeroid syndrome due to recurrent heterozygous LMNA P.T10i mutation","volume":"103","author":"Hussain","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S130810","article-title":"Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges","volume":"10","author":"Chiquette","year":"2017","journal-title":"Diabetes Metab Syndr Obes"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.94","article-title":"Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK's Haematological Malignancy research network","volume":"112","author":"Smith","year":"2015","journal-title":"Br J Cancer"},{"key":"B36","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/978-1-62703-170-7_2","article-title":"Epidemiology and prognosis of T-cell lymphoma","volume-title":"T-cell lymphomas","author":"Wang","year":"2013"},{"key":"B37","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/art.21675","article-title":"Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis","volume":"54","author":"Baecklund","year":"2006","journal-title":"Arthritis Rheum"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2008.02029.x","article-title":"Autoimmune and inflammatory disorders and risk of Malignant lymphomas\u2013an update","volume":"264","author":"Smedby","year":"2008","journal-title":"J Intern Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-06-0300","article-title":"Malignant lymphomas in autoimmunity and inflammation: A review of risks, risk factors, and lymphoma characteristics","volume":"15","author":"Smedby","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02142","article-title":"Autoantibodies against perilipin 1 as a cause of acquired generalized lipodystrophy","volume":"9","author":"Corvillo","year":"2018","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.semcancer.2013.12.001","article-title":"Lymphoma development in patients with autoimmune and inflammatory disorders\u2013what are the driving forces","volume":"24","author":"Baecklund","year":"2014","journal-title":"Semin Cancer Biol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1210\/jcemcr\/luae069","article-title":"A novel subtype of acquired generalized lipodystrophy associated with subcutaneous panniculitis-like T-cell lymphoma","volume":"2","author":"Hoff","year":"2024","journal-title":"JCEM Case Rep"},{"key":"B43","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1096\/fsb2fasebj.12.1.57","article-title":"Leptin regulates proinflammatory immune responses","volume":"12","author":"Loffreda","year":"1998","journal-title":"FASEB J"},{"key":"B44","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/29795","article-title":"Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression","volume":"394","author":"Lord","year":"1998","journal-title":"Nature"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.622468","article-title":"The role of the adipokine leptin in immune cell function in health and disease","volume":"11","author":"Kiernan","year":"2020","journal-title":"Front Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-1220","article-title":"Leptin replacement therapy modulates circulating lymphocyte subsets and cytokine responsiveness in severe lipodystrophy","volume":"91","author":"Oral","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.84.10.5999","article-title":"Human leptin deficiency caused by a missense mutation: multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects","volume":"84","author":"Ozata","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0199052","article-title":"Causes of death in patients with Berardinelli-Seip congenital generalized lipodystrophy","volume":"13","author":"Lima","year":"2018","journal-title":"PloS One"},{"key":"B49","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.imlet.2023.08.007","article-title":"Immune dysregulation as a leading principle for lymphoma development in diverse immunological backgrounds","volume":"263","author":"Kolijn","year":"2023","journal-title":"Immunol Lett"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1702693","article-title":"Post-transplantation lymphoproliferative disorders in adults","volume":"378","author":"Dierickx","year":"2018","journal-title":"N Engl J Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-06-1069","article-title":"Non-hodgkin lymphoma secondary to cancer chemotherapy","volume":"16","author":"Krishnan","year":"2007","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101674","article-title":"Lymphomas associated with epstein-barr virus infection in 2020: results from a large, unselected case series in France","volume":"54","author":"Donzel","year":"2022","journal-title":"EClinicalMedicine"},{"key":"B53","doi-asserted-by":"publisher","first-page":"20210130","DOI":"10.3390\/medsci9010005","article-title":"Epidemiology of non-hodgkin\u2019s lymphoma","volume":"9","author":"Thandra","year":"2021","journal-title":"Med Sci (Basel)"},{"key":"B54","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1080\/17446651.2020.1735360","article-title":"Diagnostic strategies and clinical management of lipodystrophy","volume":"15","author":"Foss-Freitas","year":"2020","journal-title":"Expert Rev Endocrinol Metab"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2006.02888.x","article-title":"Peripheral T-cell lymphoma presenting as lipoatrophy and nodules","volume":"45","author":"Yiannias","year":"2006","journal-title":"Int J Dermatol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.12185","article-title":"Acquired generalized lipodystrophy associated with peripheral T cell lymphoma with cutaneous infiltration","volume":"54","author":"Aslam","year":"2015","journal-title":"Int J Dermatol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1186\/s40842-019-0076-9","article-title":"Diagnosis of acquired generalized lipodystrophy in a single patient with T-cell lymphoma and no exposure to metreleptin","volume":"5","author":"Esfandiari","year":"2019","journal-title":"Clin Diabetes Endocrinol"},{"key":"B58","volume-title":"Endocrine Reviews","author":"Ebihara","year":""},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.4158\/ACCR-2019-0366","article-title":"Unusual presentations of LMNA-associated lipodystrophy with complex phenotypes and generalized fat loss: when the genetic diagnosis uncovers novel features","volume":"6","author":"de Andrade","year":"2020","journal-title":"AACE Clin Case Rep"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.53.1713","article-title":"Primary intestinal follicular lymphoma and premature atherosclerosis in a Japanese diabetic patient with atypical familial partial lipodystrophy","volume":"53","author":"Iwanishi","year":"2014","journal-title":"Intern Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2018.06.011","article-title":"Juvenile dermatomyositis forty years on: case report","volume":"28","author":"Rego de Figueiredo","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1978.03630330097036","article-title":"Generalized lipodystrophy, scleroderma, and hodgkin\u2019s disease","volume":"138","author":"Hall","year":"1978","journal-title":"Arch Intern Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvac150.065","article-title":"Lymphoma in congenital leptin deficiency: comorbidity or adverse effect","volume":"6","author":"Torchen","year":""},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaa046.1059","article-title":"Congenital leptin deficiency: clinical insights from the first reported US cases","volume":"4","author":"Torchen","year":""}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1582715\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T04:10:47Z","timestamp":1747800647000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1582715\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":64,"alternative-id":["10.3389\/fendo.2025.1582715"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1582715","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,21]]},"article-number":"1582715"}}